Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Marci L. Chew"'
Autor:
Nicholas J. Simmonds, C. Kors van der Ent, Carla Colombo, Nils Kinnman, Cynthia DeSouza, Teja Thorat, Marci L. Chew, Keval Chandarana, Carlo Castellani
Publikováno v:
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
VOCAL was an observational study of the effect of long-term ivacaftor on real-world clinical outcomes and healthcare resource utilization (HCRU) in people with cystic fibrosis (pwCF) in Italy, the Netherlands, and the UK.pwCF aged ≥6 years with non
Publikováno v:
Journal of clinical pharmacologyReferences. 59(11)
A population pharmacokinetic (PK) model was developed to characterize the properties of pregabalin extended-release (ER) in healthy volunteers and was subsequently applied to patient data from efficacy/safety studies investigating pregabalin ER for p
Autor:
Marci L. Chew, Thean Yeoh, Juanzhi Fang, Gautam Ramchandra Ranade, Ruolun Qiu, Yali Liang, Joyce Mordenti, Brian Corrigan
Publikováno v:
Pharmaceutical Research. 33:1873-1880
Transdermal delivery has the potential to offer improved bioavailability by circumventing first-pass gut and hepatic metabolism. This study evaluated the pharmacokinetics of oral immediate release and transdermal latrepirdine in extensive and poor CY
Autor:
Peter Lockwood, Joseph M. Scavone, Tanja Alebic-Kolbah, Anna Plotka, Christine Alvey, Lynne Pauer, Laure Mendes da Costa, Marci L. Chew, Maud Allard
Publikováno v:
Journal of Human Lactation. 32:NP1-NP8
Background: Limited data exist on the presence of pregabalin in human breast milk of nursing mothers. Objectives: This study aimed to determine pregabalin concentrations in breast milk, estimate the infant daily pregabalin dose from nursing mothers,
Autor:
Verne Pitman, Christine Alvey, Jing Liu, Elizabeth A Zegarac, John M. Pellock, Donald W. Mann, Howard N. Bockbrader, Marci L. Chew
Publikováno v:
Epilepsia. 55:1934-1943
To evaluate the safety, tolerability, and pharmacokinetics (PK) of pregabalin as adjunctive therapy in children with refractory partial seizures.This was a phase 1, randomized, placebo-controlled, parallel-group, escalating-dose, multiple-dose study
Autor:
David M. Simpson, Jaren W. Landen, Jonathan Sporn, David Semel, Birol Emir, Andrew S.C. Rice, Marci L. Chew
Publikováno v:
Pain. 155:1943-1954
The objective of these studies was to assess the efficacy and safety of pregabalin in the treatment of human immunodeficiency virus (HIV)-associated neuropathic pain. Patients with HIV-associated distal sensory polyneuropathy (DSP) were randomized to
Autor:
Verne Pitman, Christine Alvey, Joseph M. Scavone, Tanja Alebic-Kolbah, Howard N. Bockbrader, Marci L. Chew, Anna Plotka
Publikováno v:
Clinical Drug Investigation. 34:627-637
Pregabalin (Lyrica®) is approved as an immediate-release (IR) formulation for administration twice (BID) or three times (TID) a day depending on indication. Once daily (QD) dosing may be appropriate for ease of clinical use and patient convenience.
Autor:
Lesley M, Arnold, Pierre, Arsenault, Cynthia, Huffman, Jeffrey L, Patrick, Michael, Messig, Marci L, Chew, Luis, Sanin, Joseph M, Scavone, Lynne, Pauer, Andrew G, Clair
Publikováno v:
Current Medical Research and Opinion. 30:2069-2083
Safety and efficacy of a once daily controlled-released (CR) formulation of pregabalin was evaluated in patients with fibromyalgia using a placebo-controlled, randomized withdrawal design.This multicenter study included 6 week single-blind pregabalin
Autor:
Lloyd Knapp, Marci L. Chew, Jacqueline A. French, Verne Pitman, Holly Posner, Victor Biton, Daniel Friedman, Christian Brandt, Sarah Dubrava
Publikováno v:
Epilepsia. 55:1220-1228
Summary Objectives To assess the efficacy and tolerability of add-on pregabalin controlled-release formulation (PGB-CR) (doses of 165 or 330 mg/day) in patients with partial-onset seizures (POS). Methods This was a randomized, double-blind (DB), para
Autor:
Marci L. Chew, Joseph M. Scavone, Luis Sanin, James N Goldenberg, Ruoyong Yang, Joseph Driscoll, James Weintraub, Cynthia L Huffman
Publikováno v:
The Clinical journal of pain. 33(7)
To assess efficacy and safety of once-daily controlled-release (CR) formulation of pregabalin in patients with postherpetic neuralgia.An enriched enrollment, randomized withdrawal trial, with 6-week single-blind pregabalin treatment phase and 13-week